TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20737642

Group type: EXPERIMENTAL
Intervention: Fenofibrate immediate release (IR) tablet formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulations containing sodium lauryl sulfate (SLS)
Number of subjects: 0
Study: 18034777

Group type: EXPERIMENTAL
Intervention: Conivaptan 40 mg/day
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Conivaptan 80 mg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 17154775

Group type: EXPERIMENTAL
Intervention: Single-process random-walk model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hybrid 2-stage model
Number of subjects: 0
Study: 15071273

Group type: EXPERIMENTAL
Intervention: Implantable defibrillator (ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 0
Study: 11074199

Group type: EXPERIMENTAL
Intervention: Coronary stent
Number of subjects: 48

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 48
Study: 9196650

Group type: EXPERIMENTAL
Intervention: Health educational leaflet
Number of subjects: 1571

Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 1571
Study: 1331992

Group type: EXPERIMENTAL
Intervention: lomefloxacin 400 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ciprofloxacin 750 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 2938551

Group type: COMPARATOR
Intervention: Implantable pump only (Group A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Implantable pump and resection (Group B)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Implantable pump and arterial embolization and portal vein branch ligation (Group C)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Implantable pump, partial resection, arterial embolization, and portal vein branch ligation (Group D)
Number of subjects: 27
Study: 28674856

Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol (FCBT)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Brinzolamide-timolol (FCBZT)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group (no antiglaucoma medications)
Number of subjects: 257
Study: 27401892

Group type: EXPERIMENTAL
Intervention: onartuzumab (10 mg/kg) plus mFOLFOX6
Number of subjects: 123

Group type: COMPARATOR
Intervention: placebo plus mFOLFOX6
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: onartuzumab (10 mg/kg) plus mFOLFOX6 in MET-positive population
Number of subjects: 123

Group type: COMPARATOR
Intervention: placebo plus mFOLFOX6 in MET-positive population
Number of subjects: 123
Study: 24919684

Group type: EXPERIMENTAL
Intervention: 25% albumin plus furosemide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Furosemide alone (normal saline placebo)
Number of subjects: 50
Study: 22450591

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) for enhancing muscle strength
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) for inhibiting muscle strength
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham Kinesiotaping (placebo)
Number of subjects: 36
Study: 20860443

Group type: EXPERIMENTAL
Intervention: PW1 (final radiographic follow-up)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PW2 (both postoperative follow-up and final follow-up)
Number of subjects: 12

Group type: COMPARATOR
Intervention: RSA (Model‐based RSA using elementary geometrical shape models)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PW1
Number of subjects: 12

Group type: COMPARATOR
Intervention: RSA
Number of subjects: 12
Study: 18242415

Group type: EXPERIMENTAL
Intervention: Nutritious supplement (atole)
Number of subjects: 1424

Group type: COMPARATOR
Intervention: Less nutritious supplement (fresco)
Number of subjects: 1424
Study: 16193892

Group type: EXPERIMENTAL
Intervention: Avonex® (interferon beta-la) 30 μg, intramuscular, once weekly
Number of subjects: 0
Study: 12091066

Group type: EXPERIMENTAL
Intervention: Baseline Quality of Life (QoL) above median (67)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Baseline Quality of Life (QoL) below median (67)
Number of subjects: 501
Study: 10628579

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (tricyclic antidepressants, antiserotonin antidepressants, selective serotonin reuptake inhibitors, or multiple agents)
Number of subjects: 6595

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 6595

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 6595
Study: 8787254

Group type: EXPERIMENTAL
Intervention: 21-gauge needle
Number of subjects: 160

Group type: COMPARATOR
Intervention: 25-gauge needle
Number of subjects: 160
Study: 2025805

Group type: EXPERIMENTAL
Intervention: Topical Xylocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6277018

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg given twice daily for 4 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ranitidine for a further 4-week period after initial treatment
Number of subjects: 65
Study: 31936725

Group type: EXPERIMENTAL
Intervention: Once-weekly sprint interval training (SIT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Twice-weekly sprint interval training (SIT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 34
Study: 31045666

Group type: EXPERIMENTAL
Intervention: Open reduction and volar plate fixation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Plaster immobilization
Number of subjects: 92
Study: 28931010

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 171
Study: 27216240

Group type: EXPERIMENTAL
Intervention: Tangshen Formula (TSF) plus irbesartan
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo plus irbesartan
Number of subjects: 144
Study: 24713285

Group type: EXPERIMENTAL
Intervention: VA group (sole VA supplementation)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: FE group (sole iron supplementation)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: VF group (combined VA and iron supplementation)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: VA group
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: FE group
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: VF group
Number of subjects: 445

Group type: COMPARATOR
Intervention: CO group (control group, no supplementation)
Number of subjects: 445
Study: 23154554

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 811

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 811
Study: 19916344

Group type: EXPERIMENTAL
Intervention: Infant massage intervention (approximately 2 months duration)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (typical parent education curriculum)
Number of subjects: 25
Study: 17709660

Group type: EXPERIMENTAL
Intervention: Narrowband UV-B phototherapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (nonirradiated body halves)
Number of subjects: 14
Study: 15355358

Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (hydroquinone cream and sunscreens)
Number of subjects: 17
Study: 12011721

Group type: EXPERIMENTAL
Intervention: HBO (100% oxygen at 253 kPa [2.5 ATA] for 60 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham (atmospheric air at 132 kPa [1.3 ATA] for 60 min)
Number of subjects: 12
Study: 9833745

Group type: EXPERIMENTAL
Intervention: Mexiletine (600 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 22
Study: 7865920

Group type: EXPERIMENTAL
Intervention: Parental language training sessions (experimental group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual, direct speech and language therapy (third group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General learning skills training sessions (parental control group)
Number of subjects: 0
Study: 2688528

Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 322

Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 322
Study: 1113235

Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) formula
Number of subjects: 16

Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) formula
Number of subjects: 16
Study: 30958045

Group type: EXPERIMENTAL
Intervention: 40 mg octacosanol intake
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 28385303

Group type: EXPERIMENTAL
Intervention: Tele-education system (pretest, ROP tutorial, ROP educational chapters, and posttest)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tele-education system
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (pretest and posttest only)
Number of subjects: 58
Study: 24890674

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream or ointment administered once or twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 23745532

Group type: EXPERIMENTAL
Intervention: Underlay graft
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Overlay graft
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Button graft
Number of subjects: 195
Study: 20940336

Group type: EXPERIMENTAL
Intervention: PI-2301 (0.035 to 60 mg subcutaneous injection)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PI-2301 (10, 30, and 60 mg cohorts)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PI-2301 (1, 3, or 10 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PI-2301 (30 or 60 mg)
Number of subjects: 56
Study: 19463459

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 1593

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1593
Study: 17963520

Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 5025

Group type: COMPARATOR
Intervention: Barium enema or colonoscopy (standard investigation)
Number of subjects: 5025
Study: 15236997

Group type: EXPERIMENTAL
Intervention: Early-hCG group (10000 IU hCG administered as soon as at least three follicles were >=17 mm on ultrasound)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Late-hCG group (10000 IU hCG administered 2 days after the criterion was met)
Number of subjects: 413
Study: 11585881

Group type: EXPERIMENTAL
Intervention: L&W with tPA (4 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanical thrombolysis with PTD
Number of subjects: 40

Group type: COMPARATOR
Intervention: L&W with urokinase (UK) (250,000 U)
Number of subjects: 40
Study: 9824020

Group type: EXPERIMENTAL
Intervention: BiPAP S/T-D
Number of subjects: 27

Group type: COMPARATOR
Intervention: Servo Ventilator 900C
Number of subjects: 27
Study: 8030656

Group type: COMPARATOR
Intervention: Placebo (intravenous saline)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 126
Study: 2656877

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CTZ)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (CTZ) or Cefamandole (CFM)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 175
Study: 30803387

Group type: EXPERIMENTAL
Intervention: Neuronavigated rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-navigated rTMS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 28208688

Group type: EXPERIMENTAL
Intervention: Sleep Restricted (SR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hot and Sleep Restricted (HOT + SR)
Number of subjects: 30
Study: 25607905

Group type: COMPARATOR
Intervention: Retinol 0.25%
Number of subjects: 65

Group type: COMPARATOR
Intervention: Retinol 0.5%
Number of subjects: 65

Group type: COMPARATOR
Intervention: Retinol 1.0%
Number of subjects: 65
Study: 24320206

Group type: EXPERIMENTAL
Intervention: Bidirectional knotless barbed suture (Quill™‐0; Angiotech Pharmaceuticals, Inc.)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard sutures (extracorporeal poliglecaprone 25; Monocryl™‐1 or intracorporeal polyglactin 910; Vicryl™‐1)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months, 6 months, and 1 year after surgery
Number of subjects: 117
Study: 22078155

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (50 mg/mL, 5 mg per 0.1 mL, administered once in 1 nostril)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intravenous midazolam (2.5 mg, infused over 10 seconds)
Number of subjects: 7
Study: 18653268

Group type: EXPERIMENTAL
Intervention: ARB treatment (valsartan, candesartan, losartan)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No ARB (control)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ARB treatment
Number of subjects: 180
Study: 15071279

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 10195713

Group type: EXPERIMENTAL
Intervention: Paladai
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cup
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bottle
Number of subjects: 100
Study: 7495191

Group type: EXPERIMENTAL
Intervention: Vigabatrin as add-on therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vigabatrin monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine monotherapy
Number of subjects: 0
Study: 1369725

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (2 x 316.5 mg tablets daily with meals) for 6 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (2 tablets daily during washout and treatment)
Number of subjects: 94
Study: 463771

Group type: EXPERIMENTAL
Intervention: Alpha methyldopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 30709958

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy for 3 months
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Low baseline levels of C-reactive protein (CRP)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Low baseline levels of leptin
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: High baseline levels of tumor necrosis factor receptor I (TNF-RI)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: High baseline levels of vascular cell adhesion molecule 1 (VCAM-1)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Combined score based on CRP, leptin, TNF-RI, and VCAM-1
Number of subjects: 298
Study: 28682289

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (HP) 40%
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ozone (OZ)
Number of subjects: 26
Study: 25939684

Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 lymphadenectomy
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Open D2 lymphadenectomy
Number of subjects: 1050
Study: 23645886

Group type: EXPERIMENTAL
Intervention: ITCA 650 20 μg/day
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: ITCA 650 40 μg/day
Number of subjects: 286

Group type: COMPARATOR
Intervention: Ex-BID (twice-daily exenatide injections) 5 → 10 μg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: ITCA 650 60 μg/day
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: ITCA 650 80 μg/day
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: All ITCA 650 groups except 20 → 20 μg/day
Number of subjects: 286
Study: 21873897

Group type: EXPERIMENTAL
Intervention: 1 strength maintenance training session per week (group 2 + 1; n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 1 strength maintenance training session every second week (group 2 + 0.5; n = 7)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 19678443

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer (Heraeus Kulzer)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: UltraEZ (Ultradent Products, Inc)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Duraphat (Colgate Oral Pharmaceuticals, Inc)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 52
Study: 17920503

Group type: EXPERIMENTAL
Intervention: Herbst appliance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Begg appliance
Number of subjects: 0
Study: 15284257

Group type: EXPERIMENTAL
Intervention: FEC 100 (epirubicin 100 mg/m²)
Number of subjects: 150

Group type: COMPARATOR
Intervention: FEC 50 (epirubicin 50 mg/m²)
Number of subjects: 150
Study: 11528252

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) >500 million units total dose
Number of subjects: 291

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) <=500 million units total dose
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) >500 million units total dose in patients with histology F2 or F3
Number of subjects: 291

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) duration <=24 weeks
Number of subjects: 291

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN) duration >24 weeks
Number of subjects: 291
Study: 9761101

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7836521

Group type: EXPERIMENTAL
Intervention: Motile spermatozoa from subfertile men with sperm precursor excess
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motile spermatozoa from fertile controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motile spermatozoa from subfertile men with leukocyte excess
Number of subjects: 0
Study: 29322365

Group type: EXPERIMENTAL
Intervention: Iron pots (Group A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aluminum pots (Group B)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 10
Study: 27136892

Group type: EXPERIMENTAL
Intervention: Nostalgic reverie
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordinary event writing
Number of subjects: 0
Study: 24946227

Group type: EXPERIMENTAL
Intervention: ENRICH (Environmental Interventions in Children's Homes)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: High PA-promoting environments
Number of subjects: 799

Group type: COMPARATOR
Intervention: Low PA-promoting environments
Number of subjects: 799
Study: 22264616

Group type: EXPERIMENTAL
Intervention: Postoperative education during child's surgical procedure
Number of subjects: 70

Group type: COMPARATOR
Intervention: Postoperative education just before discharge home
Number of subjects: 70
Study: 20836948

Group type: EXPERIMENTAL
Intervention: Standardized illustrations (flip chart)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Individualized drawings
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Both standardized and individualized illustrations
Number of subjects: 189

Group type: COMPARATOR
Intervention: Verbal information
Number of subjects: 189
Study: 19422759

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (olanzapine, quetiapine, risperidone) combined with SSRI and cognitive-behavioral therapy (CBT) for 1 year
Number of subjects: 44

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs) plus cognitive-behavioral therapy (CBT) for 1 year
Number of subjects: 44
Study: 16683384

Group type: EXPERIMENTAL
Intervention: Directed physiotherapy regimen of 19 exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Free physiotherapy following biomechanical physiological movements of the shoulder
Number of subjects: 60
Study: 15385013

Group type: COMPARATOR
Intervention: Propofol (2.5 mg x kg(‐1) bolus followed by 100 microg x kg(‐1) x min(‐1) infusion)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg x kg(‐1) bolus after 0.5 mg x kg(‐1) bolus of ketamine followed by 75 microg x kg(‐1) x min(‐1) infusion)
Number of subjects: 43
Study: 11527684

Group type: EXPERIMENTAL
Intervention: Neoadjuvant regional hyperthermia (RHT) combined with chemotherapy (etoposide, ifosfamide, doxorubicin)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Neoadjuvant regional hyperthermia (RHT) combined with chemotherapy
Number of subjects: 59
Study: 9249621

Group type: EXPERIMENTAL
Intervention: Epilepsy patients
Number of subjects: 39
Study: 8495829

Group type: EXPERIMENTAL
Intervention: Esophageal variceal ligation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Esophageal variceal sclerotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study: 2892257

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg nocte
Number of subjects: 777

Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte
Number of subjects: 777
Study: 28501869

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) progesterone 50 mg in oil, single daily injection
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vaginal progesterone 200 mg micronized, 3 times daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) progesterone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Vaginal progesterone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both IM and vaginal progesterone
Number of subjects: 34
Study: 27464544

Group type: EXPERIMENTAL
Intervention: Once Vex(GM-CSF) and adriamycin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Adriamycin
Number of subjects: 102
Study: 25002196

Group type: EXPERIMENTAL
Intervention: Shun-Qi-Tong-Xie Granule (SQTX Granule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22436955

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 1000
Study: 20393026

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) with 4 weeks' PSK administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preoperative chemoradiotherapy (CRT)
Number of subjects: 30
Study: 18468761

Group type: EXPERIMENTAL
Intervention: Palatal mucoadhesive tablet containing herbal formulation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Herbal formulation ingredients (sage, Echinacea, Lavender, Mastic gum)
Number of subjects: 56
Study: 15991060

Group type: EXPERIMENTAL
Intervention: Lidocaine anal block (1 percent lidocaine)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 26
Study: 12917867

Group type: EXPERIMENTAL
Intervention: Home-based therapy (n=34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hospital rehabilitation (n=32)
Number of subjects: 66
Study: 10343785

Group type: EXPERIMENTAL
Intervention: lorazepam (0.038 mg kg‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16